Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors

Abstract

By systematic analysis of a human testis library, we have isolated the hH-Rev107-3 cDNA, identical to hH-Rev107-1 cDNA, which was previously described as a class II tumor suppressor gene. In this study, two transcripts (1 and 0.8 kb) were detected by Northern blot in all human tissues, excepted in thymus. The strongest expression was found in testis, skeletal muscle and heart. These two mRNA are probably transcribed from only one gene that we mapped to the q12-q13 region of the chromosome 11. In human testis, hH-Rev107 gene expression was localized, by in situ hybridization, within the round spermatids. To investigate a possible role for hH-Rev107 protein in testicular malignant growth, we examined the expression of this gene in germ cell tumors. A strong hH-Rev107 gene expression was observed in normal testis as well as in samples with preinvasive carcinoma in situ but was completely absent in overt tumors, both seminomas and non-seminomas. By in situ hybridization, CIS was found hH-Rev107 positive and tumor negative. A semi-quantitative assessment of hH-Rev107 mRNA level in testicular germ cell tumors, by RT–PCR, exhibited a ninefold decrease in the gene expression. No gross structural aberrations of hH-Rev107 gene were detected in these human primary tumors. The results suggest that down-regulation of hH-Rev107 may be associated with invasive progression of testicular germ cell tumors.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Bartkova J, Thullberg M, Rajpert-De Meyts E, Skakkebaek NE, Bartek J . 2000 Int. J. Cancer 85: 370–375

  • Bos JL . 1989 Cancer Res. 49: 4682–4689

  • Braun RE . 1998 Semin. Cell. Dev. Biol. 9: 483–489

  • Bulle F, Lespinasse J, Pawlak A, Vadot E, Sastre J, Noel B, Guellaen G . 1996 Ann. Genet. 39: 139–143

  • Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159

  • DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RA, Nagpal S . 1998 Proc. Natl. Acad. Sci. USA 95: 14811–14815

  • Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, Hager C, DiMao D, Hazarika P, Jackson B, Breuer-McHam J, Young J, Clayman G, Lippman SM, Chandraratna RA, Robinson NA, Deucher A, Eckert RL, Nagpal S . 2000 Clin. Cancer Res. 6: 3249–3259

  • Erickson RP . 1990 Trends Genet. 6: 264–269

  • Hajnal A, Klemenz R, Schafer R . 1994 Oncogene 9: 479–490

  • Hecht NB . 1998 Bioessays 20: 555–561

  • Huang SL, Shyu RY, Yeh MY, Jiang SY . 2000 Mol. Cell. Endocrinol. 159: 15–24

  • Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schafer R . 1998 Oncogene 17: 1305–1312

  • Lee SW, Tomasetto C, Sager R . 1991 Proc. Natl. Acad. Sci. USA 88: 2825–2829

  • Levy I, Wu YQ, Roeckel N, Bulle F, Pawlak A, Siegrist S, Mattei MG, Guellaen G . 1996 FEBS Lett. 382: 276–280

  • Mattei MG, Philip N, Passage E, Moisan JP, Mandel JL, Mattei JF . 1985 Hum. Genet. 69: 268–271

  • Moul JW, Theune SM, Chang EH . 1992 Genes Chromosomes Cancer 5: 109–118

  • Mulder MP, Keijzer W, Verkerk A, Boot AJ, Prins ME, Splinter TA, Bos JL . 1989 Oncogene 4: 1345–1351

  • Pawlak A, Toussaint C, Levy I, Bulle F, Poyard M, Barouki R, Guellaen G . 1995 Genomics 26: 151–158

  • Peckham M . 1988 Acta. Oncol. 27: 439–453

  • Rajpert-De Meyts E, Jorgensen N, Brondum-Nielsen K, Muller J, Skakkebaek NE . 1998 Apmis 106: 198–204 discussion 204–206

  • Richie JP . 1993 CA Cancer J. Clin. 43: 151–175

  • Saccone S, De Sario A, Della Valle G, Bernardi G . 1992 Proc. Natl. Acad. Sci. USA 89: 4913–4917

  • Schmidt B, Ackermann R, Strohmeyer T . 1995 J. Mol. Med. 73: 355–367

  • Schmidt EE, Schibler U . 1995 Development 121: 2373–2383

  • Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R . 1997 J. Cell. Biol. 136: 935–944

  • Shuin T, Misaki H, Kubota Y, Yao M, Hosaka M . 1994 Cancer 73: 1721–1727

  • Skakkebaek NE . 1972 Lancet 2: 516–517

  • Skakkebaek NE, Berthelsen JG, Giwercman A, Muller J . 1987 Int. J. Androl. 10: 19–28

Download references

Acknowledgements

We thank Y Laperche for helpful discussion and J Hinrichsen H Kistrup and C. Deschamps for excellent technical assistances. INSERM and the Danish Cancer Society funded this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frédérique Bulle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siegrist, S., Féral, C., Chami, M. et al. hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors. Oncogene 20, 5155–5163 (2001). https://doi.org/10.1038/sj.onc.1204658

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204658

Keywords

This article is cited by

Search

Quick links